Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects
As part of a multi center, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accomp...
Gespeichert in:
| Veröffentlicht in: | The journal of nervous and mental disease 1984-10, Vol.172 (10), p.604-612 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 612 |
|---|---|
| container_issue | 10 |
| container_start_page | 604 |
| container_title | The journal of nervous and mental disease |
| container_volume | 172 |
| creator | AUGUST, GERALD J RAZ, NAFTALI PAPANICOLAOU, ANDREW C BAIRD, TERESA DAVIS HIRSH, SHARON L HSU, LOUISE L |
| description | As part of a multi center, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine. |
| doi_str_mv | 10.1097/00005053-198410000-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81251463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81251463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3003-37133eadf414341d991462e00eb3b2a03b058040f1d8fef5d64f9e0e1fe176293</originalsourceid><addsrcrecordid>eNp1UctO7DAMjdBF3OHxCUhZsboFp05f7AANDwnBBiR2UaZ1aLhpMyQtiL-nwwzs8MKW7XNs65gxLuBYQFWcwGQZZJiIqpRilSUrh1tsJjKskgLzpz9sBpCmCYIo_7LdGF8ARIESdthOjqWUCDP2fEm9cWPQne2JPwTSQ0f9wG3Pb3qj-8E64mfjYGN3yu9oDL5uqbO1dv_43FE9BL9sP6L1zj-vq7pv-Dm1-s36oB2fGzOh4j7bNtpFOtjEPfZ4OX-4uE5u769uLs5ukxqn8xMsBCLpxkghUYqmqoTMUwKgBS5SDbiArAQJRjSlIZM1uTQVAQlDosjTCvfY0XruMvjXkeKgOhtrck735MeoSpFm00icgOUaWAcfYyCjlsF2OnwoAWqlsfrWWP1o_FVaUQ83O8ZFR80PcSPq1Jfr_rt3A4X4343vFFRL2g2t-u11-AnRkYb1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81251463</pqid></control><display><type>article</type><title>Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>AUGUST, GERALD J ; RAZ, NAFTALI ; PAPANICOLAOU, ANDREW C ; BAIRD, TERESA DAVIS ; HIRSH, SHARON L ; HSU, LOUISE L</creator><creatorcontrib>AUGUST, GERALD J ; RAZ, NAFTALI ; PAPANICOLAOU, ANDREW C ; BAIRD, TERESA DAVIS ; HIRSH, SHARON L ; HSU, LOUISE L</creatorcontrib><description>As part of a multi center, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.</description><identifier>ISSN: 0022-3018</identifier><identifier>EISSN: 1539-736X</identifier><identifier>DOI: 10.1097/00005053-198410000-00003</identifier><identifier>PMID: 6384430</identifier><language>eng</language><publisher>United States: Williams & Wilkins</publisher><subject>Adolescent ; Ambulatory Care ; Attention - drug effects ; Autistic Disorder - blood ; Autistic Disorder - drug therapy ; Autistic Disorder - physiopathology ; Brain Stem - physiopathology ; Child ; Child, Preschool ; Clinical Trials as Topic ; Double-Blind Method ; Emotions - drug effects ; Evoked Potentials ; Female ; Fenfluramine - therapeutic use ; Humans ; Male ; Motor Activity - drug effects ; Patient Compliance ; Placebos ; Serotonin - blood</subject><ispartof>The journal of nervous and mental disease, 1984-10, Vol.172 (10), p.604-612</ispartof><rights>Williams & Wilkins 1984. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6384430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>AUGUST, GERALD J</creatorcontrib><creatorcontrib>RAZ, NAFTALI</creatorcontrib><creatorcontrib>PAPANICOLAOU, ANDREW C</creatorcontrib><creatorcontrib>BAIRD, TERESA DAVIS</creatorcontrib><creatorcontrib>HIRSH, SHARON L</creatorcontrib><creatorcontrib>HSU, LOUISE L</creatorcontrib><title>Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects</title><title>The journal of nervous and mental disease</title><addtitle>J Nerv Ment Dis</addtitle><description>As part of a multi center, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.</description><subject>Adolescent</subject><subject>Ambulatory Care</subject><subject>Attention - drug effects</subject><subject>Autistic Disorder - blood</subject><subject>Autistic Disorder - drug therapy</subject><subject>Autistic Disorder - physiopathology</subject><subject>Brain Stem - physiopathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Emotions - drug effects</subject><subject>Evoked Potentials</subject><subject>Female</subject><subject>Fenfluramine - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Patient Compliance</subject><subject>Placebos</subject><subject>Serotonin - blood</subject><issn>0022-3018</issn><issn>1539-736X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UctO7DAMjdBF3OHxCUhZsboFp05f7AANDwnBBiR2UaZ1aLhpMyQtiL-nwwzs8MKW7XNs65gxLuBYQFWcwGQZZJiIqpRilSUrh1tsJjKskgLzpz9sBpCmCYIo_7LdGF8ARIESdthOjqWUCDP2fEm9cWPQne2JPwTSQ0f9wG3Pb3qj-8E64mfjYGN3yu9oDL5uqbO1dv_43FE9BL9sP6L1zj-vq7pv-Dm1-s36oB2fGzOh4j7bNtpFOtjEPfZ4OX-4uE5u769uLs5ukxqn8xMsBCLpxkghUYqmqoTMUwKgBS5SDbiArAQJRjSlIZM1uTQVAQlDosjTCvfY0XruMvjXkeKgOhtrck735MeoSpFm00icgOUaWAcfYyCjlsF2OnwoAWqlsfrWWP1o_FVaUQ83O8ZFR80PcSPq1Jfr_rt3A4X4343vFFRL2g2t-u11-AnRkYb1</recordid><startdate>198410</startdate><enddate>198410</enddate><creator>AUGUST, GERALD J</creator><creator>RAZ, NAFTALI</creator><creator>PAPANICOLAOU, ANDREW C</creator><creator>BAIRD, TERESA DAVIS</creator><creator>HIRSH, SHARON L</creator><creator>HSU, LOUISE L</creator><general>Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198410</creationdate><title>Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects</title><author>AUGUST, GERALD J ; RAZ, NAFTALI ; PAPANICOLAOU, ANDREW C ; BAIRD, TERESA DAVIS ; HIRSH, SHARON L ; HSU, LOUISE L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3003-37133eadf414341d991462e00eb3b2a03b058040f1d8fef5d64f9e0e1fe176293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Adolescent</topic><topic>Ambulatory Care</topic><topic>Attention - drug effects</topic><topic>Autistic Disorder - blood</topic><topic>Autistic Disorder - drug therapy</topic><topic>Autistic Disorder - physiopathology</topic><topic>Brain Stem - physiopathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Emotions - drug effects</topic><topic>Evoked Potentials</topic><topic>Female</topic><topic>Fenfluramine - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Patient Compliance</topic><topic>Placebos</topic><topic>Serotonin - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AUGUST, GERALD J</creatorcontrib><creatorcontrib>RAZ, NAFTALI</creatorcontrib><creatorcontrib>PAPANICOLAOU, ANDREW C</creatorcontrib><creatorcontrib>BAIRD, TERESA DAVIS</creatorcontrib><creatorcontrib>HIRSH, SHARON L</creatorcontrib><creatorcontrib>HSU, LOUISE L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of nervous and mental disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AUGUST, GERALD J</au><au>RAZ, NAFTALI</au><au>PAPANICOLAOU, ANDREW C</au><au>BAIRD, TERESA DAVIS</au><au>HIRSH, SHARON L</au><au>HSU, LOUISE L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects</atitle><jtitle>The journal of nervous and mental disease</jtitle><addtitle>J Nerv Ment Dis</addtitle><date>1984-10</date><risdate>1984</risdate><volume>172</volume><issue>10</issue><spage>604</spage><epage>612</epage><pages>604-612</pages><issn>0022-3018</issn><eissn>1539-736X</eissn><abstract>As part of a multi center, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.</abstract><cop>United States</cop><pub>Williams & Wilkins</pub><pmid>6384430</pmid><doi>10.1097/00005053-198410000-00003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3018 |
| ispartof | The journal of nervous and mental disease, 1984-10, Vol.172 (10), p.604-612 |
| issn | 0022-3018 1539-736X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_81251463 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Ambulatory Care Attention - drug effects Autistic Disorder - blood Autistic Disorder - drug therapy Autistic Disorder - physiopathology Brain Stem - physiopathology Child Child, Preschool Clinical Trials as Topic Double-Blind Method Emotions - drug effects Evoked Potentials Female Fenfluramine - therapeutic use Humans Male Motor Activity - drug effects Patient Compliance Placebos Serotonin - blood |
| title | Fenfluramine Treatment in Infantile Autism: Neurochemical, Electrophysiological, and Behavioral Effects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A30%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fenfluramine%20Treatment%20in%20Infantile%20Autism:%20Neurochemical,%20Electrophysiological,%20and%20Behavioral%20Effects&rft.jtitle=The%20journal%20of%20nervous%20and%20mental%20disease&rft.au=AUGUST,%20GERALD%20J&rft.date=1984-10&rft.volume=172&rft.issue=10&rft.spage=604&rft.epage=612&rft.pages=604-612&rft.issn=0022-3018&rft.eissn=1539-736X&rft_id=info:doi/10.1097/00005053-198410000-00003&rft_dat=%3Cproquest_cross%3E81251463%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81251463&rft_id=info:pmid/6384430&rfr_iscdi=true |